XBiotech Inc.
NASDAQ Global SelectTotal Valuation
XBiotech Inc. carries a market capitalization of 60.98M, placing it among publicly traded companies globally. Its enterprise value stands at -39.41M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 60.98M |
| Enterprise Value | -39.41M |
Share Statistics
XBiotech Inc. currently has 30.49M shares outstanding.
| Shares Outstanding | 30.49M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.55 |
| P/TBV Ratio | 0.55 |
| P/FCF Ratio | -1.73 |
| P/OCF Ratio | -1.72 |
Financial Position
XBiotech Inc. maintains a current ratio of 33.15, meaning it holds 33.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 33.15 |
| Quick Ratio | 32.75 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -29.94 |
| Return on Assets (ROA) | -28.90 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 273,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
XBiotech Inc.'s stock has declined approximately -19.35484% over the past 52 weeks. The 50-day moving average sits at 2.22, while the 200-day moving average is 2.35.
| Beta (5Y) | N/A |
| 52-Week Price Change | -19.35484% |
| 50-Day Moving Average | 2.22 |
| 200-Day Moving Average | 2.35 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -46.78M, while operating income came in at -48.22M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -48.22M |
| Pretax Income | -44.86M |
| Net Income | -45.13M |
| EBITDA | -46.78M |
| EBIT | -48.22M |
| Earnings Per Share (EPS) | -1.48 |
Balance Sheet
Total book value stands at 128.46M, with working capital of 107.81M providing operational flexibility.
| Cash & Cash Equivalents | 109.53M |
| Total Debt | N/A |
| Net Debt | -109.53M |
| Equity (Book Value) | 128.46M |
| Book Value Per Share | 4.21 |
| Working Capital | 107.81M |
Cash Flow
XBiotech Inc. produced -40.69M in operating cash flow over the past twelve months. After subtracting -144,000.00 in capital expenditures, free cash flow totaled -40.84M - equivalent to -1.34 per share.
| Operating Cash Flow | -40.69M |
| Capital Expenditures | -144,000.00 |
| Free Cash Flow | -40.84M |
| FCF Per Share | -1.34 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -57.83 |
Scores
XBiotech Inc. posts an Altman Z-Score of 6.33, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.33 |